• Skip to main content
  • Skip to primary sidebar

Tracking Health and Wellness Applications of Brain Science

Spanish
sb-logo-with-brain
  • Resources
    • Monthly eNewsletter
    • Solving the Brain Fitness Puzzle
    • The SharpBrains Guide to Brain Fitness
    • How to evaluate brain training claims
    • Resources at a Glance
  • Brain Teasers
    • Top 25 Brain Teasers & Games for Teens and Adults
    • Brain Teasers for each Cognitive Ability
    • More Mind Teasers & Games for Adults of any Age
  • Virtual Summits
    • 2019 SharpBrains Virtual Summit
    • Speaker Roster
    • Brainnovations Pitch Contest
    • 2017 SharpBrains Virtual Summit
    • 2016 SharpBrains Virtual Summit
    • 2015 SharpBrains Virtual Summit
    • 2014 SharpBrains Virtual Summit
  • Report: Pervasive Neurotechnology
  • Report: Digital Brain Health
  • About
    • Mission & Team
    • Endorsements
    • Public Speaking
    • In the News
    • Contact Us

Alzheimer’s & Dementia researchers challenge FDA’s approval of Aduhelm given lack of evidence for beta-amyloid as a marker

August 5, 2021 by SharpBrains

Doc­tors Blast Bio­gen Alzheimer Approval as ‘Reg­u­la­to­ry Fail­ure’ (Bloomberg):

Top researchers who advised the U.S. Food and Drug Admin­is­tra­tion on Bio­gen Inc.’s Alzheimer’s drug blast­ed the agency for approv­ing it, call­ing the deci­sion a “reg­u­la­to­ry fail­ure” that is “at odds with the evidence.”

The New Eng­land Jour­nal of Med­i­cine opin­ion piece, signed by sev­en mem­bers of an advi­so­ry pan­el that opposed clear­ing Biogen’s Aduhelm, is anoth­er sign of per­sis­tent furor over the agency’s deci­sion … The new com­men­tary is signed by them and four oth­er pan­el mem­bers, includ­ing doc­tors from Har­vard Med­ical School, the Mayo Clin­ic, and the Uni­ver­si­ty of Cal­i­for­nia, San Francisco.

An inves­ti­ga­tion of Aduhelm’s approval “should be expe­di­tious­ly per­formed, so as to learn how this reg­u­la­to­ry fail­ure occurred and to ensure that it doesn’t occur again,” the researchers wrote.

The Statement:

Revis­it­ing FDA Approval of Adu­canum­ab (oped at The New Eng­land Jour­nal of Medicine)

The com­mit­tee was nev­er con­sult­ed about beta-amyloid’s suit­abil­i­ty as a sur­ro­gate. Indeed, the lead FDA sci­en­tist told us, “We’re not using the amy­loid as a sur­ro­gate for effi­ca­cy.” More­over, the data did not sup­port this use. An effec­tive sur­ro­gate should strong­ly cor­re­late with a clin­i­cal end point in clin­i­cal stud­ies, but an FDA sta­tis­ti­cal review of Stud­ies 301 and 302 found no evi­dence that amy­loid changes cor­re­lat­ed with cog­ni­tive or func­tion­al changes, con­clud­ing that “it is not clear that there is any link­age between reduc­tion in plaque and long term clin­i­cal change” …

The FDA’s deci­sion is at odds with the evi­dence and with the agency’s bio­sta­tis­ti­cal review. The over­whelm­ing unmet need in this com­mon and dev­as­tat­ing dis­ease should dri­ve research invest­ments, not low­er­ing of reg­u­la­to­ry stan­dards that Amer­i­cans rely on for safe and effec­tive med­i­cines. The FDA has released key inter­nal reviews, but they nei­ther pro­vide a per­sua­sive sci­en­tif­ic basis for declar­ing beta-amy­loid a rea­son­able sur­ro­gate nor jus­ti­fy the fail­ure to seek advi­so­ry-com­mit­tee input on this impor­tant ques­tion. The inter­im FDA Commissioner’s deci­sion to call for an Office of the Inspec­tor Gen­er­al inves­ti­ga­tion is appro­pri­ate, and we believe such an inves­ti­ga­tion should be expe­di­tious­ly per­formed, so as to learn how this reg­u­la­to­ry fail­ure occurred and to ensure that it doesn’t occur again. Though the deci­sion will rever­ber­ate for years, ear­ly signs of its grav­i­ty are already reflect­ed in announce­ments by two oth­er man­u­fac­tur­ers that they will seek accel­er­at­ed approval for Alzheimer’s treat­ments on the basis of amy­loid as a surrogate.

News in Context:

  • Grow­ing back­lash against the FDA approval of unproven Alzheimer’s treat­ment Aduhelm, by Biogen
  • First, do no harm? Six rea­sons to approach anti-amy­loid drug Aduhelm cau­tious­ly, if at all
  • Can the con­tro­ver­sial FDA approval of Aduhelm back­fire and delay the dis­cov­ery of actu­al Alzheimer’s treat­ments? (Yes, it can)
  • US Sen­a­tor Joe Manchin calls for a new FDA Com­mis­sion­er to replace cur­rent (act­ing) one who “has repeat­ed­ly ignored pub­lic health con­cerns and shown a dere­lic­tion of duty” over opi­oids and aducanumab
  • Health payers–including Medicare and Point32Health–to ques­tion Aduhelm pric­ing and its “rea­son­able and nec­es­sary” use

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health Tagged With: Aduhelm, Alzheimer's drug, Alzheimers-treatment, beta-amyloid, Biogen, cognitive, FDA approval, surrogate

Primary Sidebar

Top Articles on Brain Health and Neuroplasticity

  1. Can you grow your hippocampus? Yes. Here’s how, and why it matters
  2. How learning changes your brain
  3. To harness neuroplasticity, start with enthusiasm
  4. Three ways to protect your mental health during –and after– COVID-19
  5. Why you turn down the radio when you're lost
  6. Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
  7. Ten neu­rotech­nolo­gies about to trans­form brain enhance­ment & health
  8. Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
  9. What Educators and Parents Should Know About Neuroplasticity and Dance
  10. The Ten Habits of Highly Effective Brains
  11. Six tips to build resilience and prevent brain-damaging stress
  12. Can brain training work? Yes, if it meets these 5 conditions
  13. What are cognitive abilities and how to boost them?
  14. Eight Tips To Remember What You Read
  15. Twenty Must-Know Facts to Harness Neuroplasticity and Improve Brain Health

Top 10 Brain Teasers and Illusions

  1. You think you know the colors? Try the Stroop Test
  2. Check out this brief attention experiment
  3. Test your stress level
  4. Guess: Are there more brain connections or leaves in the Amazon?
  5. Quick brain teasers to flex two key men­tal mus­cles
  6. Count the Fs in this sentence
  7. Can you iden­tify Apple’s logo?
  8. Ten classic optical illu­sions to trick your mind
  9. What do you see?
  10. Fun Mental Rotation challenge
  • Check our Top 25 Brain Teasers, Games and Illusions

Join 12,620 readers exploring, at no cost, the latest in neuroplasticity and brain health.

By subscribing you agree to receive our free, monthly eNewsletter. We don't rent or sell emails collected, and you may unsubscribe at any time.

IMPORTANT: Please check your inbox or spam folder in a couple minutes and confirm your subscription.

Get In Touch!

Contact Us

660 4th Street, Suite 205,
San Francisco, CA 94107 USA

About Us

SharpBrains is an independent market research firm tracking health and performance applications of brain science. We prepare general and tailored market reports, publish consumer guides, produce an annual global and virtual conference, and provide strategic advisory services.

© 2022 SharpBrains. All Rights Reserved - Privacy Policy